Literature DB >> 26678173

Serial incorporation of a monovalent GalNAc phosphoramidite unit into hepatocyte-targeting antisense oligonucleotides.

Tsuyoshi Yamamoto1, Motoki Sawamura2, Fumito Wada2, Mariko Harada-Shiba3, Satoshi Obika4.   

Abstract

The targeting of abundant hepatic asialoglycoprotein receptors (ASGPR) with trivalent N-acetylgalactosamine (GalNAc) is a reliable strategy for efficiently delivering antisense oligonucleotides (ASOs) to the liver. We here experimentally demonstrate the high systemic potential of the synthetically-accessible, phosphodiester-linked monovalent GalNAc unit when tethered to the 5'-terminus of well-characterised 2',4'-bridged nucleic acid (also known as locked nucleic acid)-modified apolipoprotein B-targeting ASO via a bio-labile linker. Quantitative analysis of the hepatic disposition of the ASOs revealed that phosphodiester is preferable to phosphorothioate as an interunit linkage in terms of ASGPR binding of the GalNAc moiety, as well as the subcellular behavior of the ASO. The flexibility of this monomeric unit was demonstrated by attaching up to 5 GalNAc units in a serial manner and showing that knockdown activity improves as the number of GalNAc units increases. Our study suggests the structural requirements for efficient hepatocellular targeting using monovalent GalNAc and could contribute to a new molecular design for suitably modifying ASO.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Antisense oligonucleotides; Apolipoproteins; Asialoglycoprotein receptors; Bio-labile linker; Bridged nucleic acid; GalNAc; Hypercholesterolemia; Locked nucleic acid

Mesh:

Substances:

Year:  2015        PMID: 26678173     DOI: 10.1016/j.bmc.2015.11.036

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  6 in total

Review 1.  Delivery of Oligonucleotides to the Liver with GalNAc: From Research to Registered Therapeutic Drug.

Authors:  Alexandre J Debacker; Jon Voutila; Matthew Catley; David Blakey; Nagy Habib
Journal:  Mol Ther       Date:  2020-06-17       Impact factor: 11.454

Review 2.  The delivery of therapeutic oligonucleotides.

Authors:  Rudolph L Juliano
Journal:  Nucleic Acids Res       Date:  2016-04-15       Impact factor: 16.971

3.  Highly efficient silencing of microRNA by heteroduplex oligonucleotides.

Authors:  Kotaro Yoshioka; Taiki Kunieda; Yutaro Asami; Huijia Guo; Haruka Miyata; Kie Yoshida-Tanaka; Yumiko Sujino; Wenying Piao; Hiroya Kuwahara; Kazutaka Nishina; Rintaro Iwata Hara; Tetsuya Nagata; Takeshi Wada; Satoshi Obika; Takanori Yokota
Journal:  Nucleic Acids Res       Date:  2019-08-22       Impact factor: 16.971

4.  Highly Potent GalNAc-Conjugated Tiny LNA Anti-miRNA-122 Antisense Oligonucleotides.

Authors:  Tsuyoshi Yamamoto; Yahiro Mukai; Fumito Wada; Chisato Terada; Yukina Kayaba; Kaho Oh; Asako Yamayoshi; Satoshi Obika; Mariko Harada-Shiba
Journal:  Pharmaceutics       Date:  2021-05-31       Impact factor: 6.321

Review 5.  Development of Antisense Drugs for Dyslipidemia.

Authors:  Tsuyoshi Yamamoto; Fumito Wada; Mariko Harada-Shiba
Journal:  J Atheroscler Thromb       Date:  2016-07-27       Impact factor: 4.928

Review 6.  ASGR1 and Its Enigmatic Relative, CLEC10A.

Authors:  J Kenneth Hoober
Journal:  Int J Mol Sci       Date:  2020-07-08       Impact factor: 5.923

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.